Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AML-CAMS-2016 for Pediatric AML
NCT03173612Unknown
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Aug 2016
- Primary completion
- Dec 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label, single-arm trial of dasatinib in acute myeloid leukemia (AML), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Complete Remission at 7 years, Overall Survival at 60 months and 2 more. Status: unknown.
02
Drugs
dasatinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03173612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03173612.